Mouse 4T1 Breast Tumor Model
暂无分享,去创建一个
[1] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.
[2] R. Mohammad,et al. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. , 1998, International journal of molecular medicine.
[3] E. Rutgers,et al. Follow‐up after treatment of primary breast cancer , 1989, The British journal of surgery.
[4] F. Miller,et al. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.
[5] M. Amer,et al. Chemotherapy and pattern of metastases in breast cancer patients , 1982, Journal of surgical oncology.
[6] M. Laberge. [Cancer of the breast]. , 1961, Laval medical.
[7] E. Shohami,et al. Induction of antitumor immunity by indomethacin , 2000, Cancer Immunology, Immunotherapy.
[8] W. Donegan,et al. Screening for recurrent breast cancer--its effectiveness and prognostic value. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Ostrand-Rosenberg,et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ , 2000, Cancer Immunology, Immunotherapy.
[10] H. Mouridsen,et al. Incidence and methodologic aspects of the occurrence of liver metastases in recurrent breast cancer , 1987, Cancer.
[11] J. Klingelhöfer,et al. Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. , 1998, Cancer research.
[12] D. Dexter,et al. Heterogeneity of tumor cells from a single mouse mammary tumor. , 1978, Cancer research.
[13] M. Dewhirst,et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[14] B A Pulaski,et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. , 2000, Cancer research.
[15] W. Boogerd. Central nervous system metastasis in breast cancer. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] S. Ostrand-Rosenberg,et al. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.
[17] J. Sogn. Tumor immunology: the glass is half full. , 1998, Immunity.